Clive Dix News Today

Oliver Dowden’s advice on stockpiling forgets that co-operation is vital if we are to stand a chance against modern threats

Shares of C4X Discovery Holdings plc (LON:C4XD – Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 11.02 ($0.14) and traded as high as GBX 12 ($0.15). C4X Discovery shares last traded at GBX 12 ($0.15), with a volume […]

C4X Discovery Holdings plc (LON:C4XD – Get Free Report) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 11.02 ($0.14) and traded as high as GBX 12 ($0.15). C4X Discovery shares last traded at GBX 12 ($0.15), with a volume of 3,770,459 shares […]

C4X Discovery Holdings plc (LON:C4XD – Get Free Report) insider Clive Dix bought 485,320 shares of the stock in a transaction dated Monday, April 8th. The shares were bought at an average cost of GBX 10 ($0.13) per share, with a total value of £48,532 ($61,425.14). C4X Discovery Stock Down 11.1 % LON:C4XD traded down […]

Drug companies could be next in the UK market exodus if the Government doesn’t step in

C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to the recent downturn in the financial markets hampering its valuation. C4X shares...

Languishing share price and high cost of regulatory burden of AIM listing makes decision a no-brainer

Drug company C4X Discovery has announced plans to quit the London Stock Exchange's AIM next month - this is why.

The Oxfordshire based Vaccine Manufacturing and Innovation Centre (VMIC) "needs to be re-established" says taskforce boss Dr Clive Dix.

The UK needs a permanent ecosystem for rapidly developing, manufacturing, and supplying vaccines for future pandemics to ensure domestic resilience and security, a report from the now disbanded Vaccine Taskforce said.1 The report was originally prepared in December 2020 and submitted to the government, but not previously made public. Clive Dix, who headed the task force in 2020 and is now chief executive of drug company C4X Discovery, submitted the report to the House of Commons Science, Innovat...